In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Concerning Canada

Executive Summary

It's technically illegal for US citizens to buy pharmaceuticals from Canada, but that's not stopping anybody. Indeed, the trend is gaining momentum at the state level. Pharmaceutical and biotech companies have a range of options for responding to re-importation, such as emphasizing the safety risks of new purchasing channels, limiting shipments into Canada, and getting tougher in price negotiations. Making pricing a trade issue might help the industry, but it's a tough case to argue. If worse comes to worst, companies may need to take legal recourse. If re-importation continues unchallenged, it is likely to lead to US price controls.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel